Foresite Capital Management III as of March 31, 2017
Portfolio Holdings for Foresite Capital Management III
Foresite Capital Management III holds 25 positions in its portfolio as reported in the March 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Aerie Pharmaceuticals | 27.8 | $72M | 1.6M | 45.35 | |
| Alder Biopharmaceuticals | 13.0 | $34M | 1.6M | 20.80 | |
| Achaogen | 12.1 | $31M | 1.2M | 25.23 | |
| Aimmune Therapeutics | 7.6 | $20M | 912k | 21.73 | |
| Wave Life Sciences (WVE) | 7.1 | $19M | 676k | 27.50 | |
| Epizyme | 4.5 | $12M | 682k | 17.15 | |
| Bellicum Pharma | 4.3 | $11M | 918k | 12.34 | |
| Blueprint Medicines (BPMC) | 4.0 | $10M | 260k | 39.99 | |
| Nanostring Technologies (NSTGQ) | 2.4 | $6.3M | 319k | 19.87 | |
| Dermira | 2.3 | $6.0M | 176k | 34.11 | |
| Momenta Pharmaceuticals | 2.2 | $5.7M | 431k | 13.35 | |
| Protagonist Therapeutics (PTGX) | 1.7 | $4.4M | 346k | 12.81 | |
| Loxo Oncology | 1.6 | $4.2M | 100k | 42.08 | |
| Aclaris Therapeutics (ACRS) | 1.6 | $4.2M | 140k | 29.82 | |
| Ascendis Pharma A S (ASND) | 1.1 | $2.8M | 100k | 28.00 | |
| Irhythm Technologies (IRTC) | 1.0 | $2.6M | 70k | 37.59 | |
| Natera (NTRA) | 1.0 | $2.5M | 286k | 8.87 | |
| Fibrogen (FGEN) | 0.8 | $2.2M | 88k | 24.65 | |
| Intellia Therapeutics (NTLA) | 0.8 | $2.1M | 150k | 14.09 | |
| Jounce Therapeutics | 0.8 | $2.0M | 92k | 21.99 | |
| Zafgen | 0.7 | $1.7M | 371k | 4.66 | |
| Orexigen Therapeutics | 0.5 | $1.3M | 381k | 3.44 | |
| Audentes Therapeutics | 0.4 | $1.1M | 67k | 17.04 | |
| Immunomedics | 0.4 | $1.1M | 173k | 6.47 | |
| Acceleron Pharma | 0.2 | $526k | 20k | 26.45 |
